The kallikrein-kinin system (KKS) constitutes a complex multienzyme cascade that produces several bioactive kinin peptides and their derivatives including bradykinin. In addition to the classical notion of the KKS as a potent vasodilator and a mediator of inflammatory responses, recent studies suggest a link between the KKS and oxidative stress. A number of established mouse models with altered levels of KKS components opened the way to evaluate precise functions of the KKS. Here we review recent findings on the role of the KKS in cardiovascular diseases and chronic kidney diseases, and discuss potential benefits of KKS activation in these diseases.
INTRODUCTION
Kinins are generated by the proteolytic cleavage of kininogens by tissue or plasma kallikreins and other serine proteases. Kinin peptides act via two types of kinin receptors: the bradykinin B1 receptor (B1R/Bdkrb1) and the bradykinin B2 receptor (B2R/ Bdkrb2) ( Fig. 1 ). B2R is constitutively expressed in most tissues, whereas B1R is induced under stress conditions including inflammation and diabetes. Both B1R and B2R are seven transmembrane receptors coupled with G-proteins, stimulation of which elevates intracellular Ca þþ concentrations and phospholipase A2 activity and leads to the release of various mediators including nitric oxide, prostaglandins, arachidonic acids and other inflammatory agents [1] [2] [3] .
Several mouse models and human epidemiological studies have suggested that kallikrein-kinin system (KKS) activity modifies oxidative stress and disease progression in the heart and kidney. In this review we classify this evidence into three sections according to the modification step of the KKS: kinin levels; receptor activity; and mediator production.
REGULATION OF KININ LEVELS BY ANGIOTENSIN I-CONVERTING ENZYME
The estimated half-life of kinin peptides is remarkably short (less than 30 s in plasma [4] ). Active kinins are rapidly cleaved by several kinin peptidases, primarily by angiotensin I-converting enzyme (ACE), which inactivates bradykinin, kallidin (humans), and kallidin-like peptide (rodents) by removing two amino acids from the carboxyl termini of these substrates [2] . ACE also cleaves angiotensin I into an active vasoconstrictor angiotensin II, although it has higher affinity for kinins than that for angiotensin I [5] . Modest changes in ACE levels affect kinin levels more than angiotensin II levels, as supported by computer simulations demonstrating that altered ACE levels have virtually no effect on the levels of products, whereas they have marked effects on its substrates [6] .
The systemic effects of quantitatively varied ACE activities were examined by utilizing genetically engineered mice that carry different copy numbers of the ACE gene. The one-copy mice showed 62% of plasma ACE activities of the wildtype (two-copy) mice, and the three-copy mice had 144% of normal [7] . A genetic decrease in ACE activity reduced myocardial infarct size after ischemia/reperfusion injury, and the effect was completely suppressed by pretreatment with a selective B2R antagonist [8] . In the streptozotocin (STZ)-induced diabetic model, the onset of proteinuria was accelerated in three-copy diabetic mice [9] . These results indicate the protective effect of low ACE levels on oxidative stress-associated diseases in the heart and kidney.
A naturally occurring polymorphism in the human ACE gene, the I/D polymorphism, is characterized by the insertion (I allele) or the noninsertion (D allele) of a 287-bp Alu retrotransposon in intron 16 . The polymorphism is associated with differences in the plasma and tissue levels of ACE (I/I, 76%; I/D, 100%; D/D, 126% of average), and the D allele is associated with higher levels of ACE and kallikrein [10, 11] . Many studies have indicated that the D/D genotype may contribute to increased risks for cardiovascular and renal diseases [12, 13] .
Angiotensin I-converting enzyme inhibitors are the most important agents that augment KKS activity. Whereas widely recognized as an inhibitor of the renin-angiotensin-aldosterone system (RAAS), their primary function is an up-regulator of kinins rather than an inhibitor of ACE. Indeed, the minimum effective dose of an ACE inhibitor perindopril for increasing plasma bradykinin levels is much lower than that for reducing angiotensin II levels [5] . This effect, partly explained in the preferential change in kinin levels more than angiotensin levels, could also be mediated by higher affinity of bradykinin-binding sites of ACE than of the angiotensin I-binding sites by ACE inhibitor [14] . Moreover, it is proposed that ACE inhibitors are the direct or indirect allosteric enhancers of B1R and B2R [15] .
The protective role of ACE inhibitors in cardiac and renal diseases has been well documented [16] . Vasopeptidase inhibitors, which simultaneously inhibit ACE and neprilysin (NEP), a circulating enzyme that degrades vasoactive peptides including natriuretic peptides and kinins, also prevent diabetes and improve diabetic nephropathy in rat models [17, 18] . The beneficial effects of ACE inhibitors and vasopeptidase inhibitors are attenuated by a B2R antagonist in diabetic model animals, indicating that the protective effects of ACE inhibitors are mediated by B2R signaling [18] [19] [20] .
In addition to the ACE inhibitors, angiotensin receptor blockers (ARBs) are widely used drugs proven to be reno and cardio-protective. Although ARBs are considered to modulate RAAS, several studies have demonstrated that the cardio-protective effect of the ARB losartan is reduced by a selective B2R
KEY POINTS
Recent evidence suggests that the kallikrein-kinin system (KKS) has a protective role against oxidative stress and organ damage in the heart and kidney.
Phenotypes of B1RB2R-null Akita mice, which lack both of the bradykinin receptors in the diabetic background, indicate that both receptors protect against the progression of diabetic nephropathy via the production of nitric oxide and prostaglandins.
Activation of the KKS by angiotensin I-converting enzyme inhibitors and vasopeptidase inhibitors is highly beneficial in patients with diabetic complications. inhibitor, indicating that some effects of ARBs are mediated through B2R activation [21] . The mechanism remains to be elucidated; however, Bonde et al. [22] recently proposed that losartan directly binds to and activates the B2R. Angiotensin I-converting enzyme inhibitors might be most effective in diabetic patients with the D allele of the ACE gene; however, clinical studies have given conflicting results [13] . Further studies on more homogenous groups are needed to assess the therapeutic effects of ACE inhibitors in patients with different ACE genotypes.
MODULATION OF BRADYKININ RECEPTOR ACTIVITY
Recent studies suggest the protective role of B2R in oxidative stress-mediated disorders of the heart and kidney [19, 20, 23] . We have previously shown that the lack of B2R worsens diabetic complications and accelerates premature aging in Akita (Ins2 Akita/þ ) diabetic mice [23] . The Akita mice lacking B2R develop senescence-associated phenotypes including alopecia, skin atrophy, kyphosis, osteoporosis, and testicular atrophy. On the contrary, another group reported that the lack of B2R protects against the development of STZ-induced diabetic nephropathy [24] . The opposite results could possibly be caused by differences in strain and age of the mice and in the method of induction of diabetes.
Whether B1R is beneficial or detrimental in the heart or kidney remains unclear. Although lack of the B1R does not affect cardiac remodeling after myocardial infarction, blockade of B2R worsened cardiac remodeling and dysfunction in B1R knockout mice but not in wild-type mice [25] . In contrast, B1R knockout mice were protected against cardiac and renal injury [26, 27] . A recent study also shows that activation of the B1R exacerbates glomerulosclerosis [28] . However, as genetic disruptions of either receptor causes enhanced expression of the remaining receptor, these results would not directly reflect the isolated lack of either receptor.
To define the role of each receptor, we generated mice lacking both B1R and B2R [29,30 && ]. Susceptibility to renal ischemia/reperfusion injury was B1RB2R-null > B2R-null > wild-type, demonstrating that both B1R and B2R have protective roles in kidney [29] . Furthermore, the lack of both B1R and B2R in the Akita diabetic mouse exacerbates the pathological changes characteristic of diabetes, such as nephropathy, neuropathy, and osteopathy (Fig. 2) . Markedly elevated levels of plasma oxidative stress markers and enhanced renal mitochondrial DNA damage suggest that the increased oxidative stress contributes to the pathological changes in the B1RB2R-null/Akita mice [30 && ]. These results clearly demonstrate that the KKS plays a protective role in the progression of oxidative stress-related diseases, and suggest a novel therapeutic strategy in that the modulation of the KKS could be beneficial for the treatment or prevention of these diseases.
In contrast to the deleterious effect of B1R and B2R deficiency in the kidney, no significant changes in cardiac structure or function were observed in B1RB2R-null mice or B1RB2R-null/Akita mice, although some parameters of cardiac dysfunction were decreased in B1RB2R-null/Akita mice [31, 32] . The different susceptibilities of the heart and kidney imply the tissue-specific distributions and functions of each receptor.
In a human polymorphism in the B2R gene (þ9/À9 bp insertion/deletion), the insertion (þ9) allele is associated with decreased B2R gene transcription. The þ9/þ9 genotype is correlated with greater cardiovascular risk including increased leftventricular hypertrophic responses and higher systolic blood pressure, implying a harmful effect of the þ9 allele [33] . In contrast, the þ9 allele is associated with a decreased progression of nephropathy in type 1 and type 2 diabetic patients [34] . The association between þ9/À9 polymorphism and risks of the other oxidative stress-related diseases requires further clinical studies.
INTRACELLULAR MEDIATOR: NITRIC OXIDE AND PROSTAGLANDINS
Reactive oxygen species (ROS), generated mainly by mitochondrial oxidative phosphorylation, are considered to be the primary cause of aging through their damage to DNA [35] . Dias et al. [36] reported that activation of B1R increases the oxidative stress through the activation of NADPH oxidase in the vasculature in a rat model. In contrast, several studies indicate that the B2R may contribute to reducing ROS. In STZ-treated hyperglycemic rats, bradykinin reduces hydrogen peroxide and a biomarker of oxidative stress. The protective effects of ACE inhibitors against oxidative stress are attenuated by a B2R antagonist [37] .
The KKS may contribute to the reduction of oxidative stress via nitric oxide and prostaglandin synthesis (Fig. 1) . Nitric oxide negatively regulates mitochondrial oxidative phosphorylation by inhibiting cytochrome c oxidase, which is a key enzyme in the electron transport chain [38] . The stimulation both of B1R and B2R activates endothelial nitric oxide synthase (NOS) (eNOS/NOS3) leading to low and transient production of nitric oxide, and activates inducible NOS (iNOS/NOS2), facilitating higher and prolonged release of nitric oxide [2, 3, 39] . Indeed, urinary nitric oxide metabolites in B2R-null mice are lower than in wild-type [40] , and the plasma nitric oxide metabolites are lower in B1RB2R-null mice than in wild-type [29] . A polymorphism in the intron 4 of the human eNOS gene is associated with an increased risk for diabetic nephropathy, and a modest decrease in eNOS enhances the development of nephropathy in diabetic mice [41] . Bradykinin reduces mitochondrial superoxide generation in human vascular endothelial cells, which is partly reversed by a NOS inhibitor [29] . Bradykinin also protects bovine aorta endothelial cells from ROS-induced DNA damage and senescence through B2R-mediated nitric oxide production [42] . Therefore, bradykinin-mediated nitric oxide production has the potential of preventing ROS-induced pathogenesis.
Recent studies also suggest the protective effect of prostaglandins against oxidative stress. PGI2 overexpression in renal tubular cells decreases aminoglycoside-induced production of ROS and prevents apoptosis of these cells [43] . A PGI2 agonist, cicaprost, attenuates the progression of diabetic renal injury in STZ-treated rats [44] . Therefore, the protective effect of KKS may partially be mediated by nitric oxide and prostaglandins.
CONCLUSION
ACE inhibitors have proven effective in long-term usage for the treatment of a constellation of cardiac and renal diseases. Although the RAAS has been implicated in the pathogenesis, recent studies indicate that the benefits of the ACE inhibitors are independent of the antihypertensive properties [45] . Meanwhile, accumulating evidence suggests that potentiating the activity of KKS can protect against the progression of these diseases, by suppressing oxidative stress presumably via production of nitric oxide and prostaglandins. Thus, the cardio and reno-protective effect of ACE inhibitors could be largely exerted by the activation of the KKS.
Studies using B1RB2R-null mice indicate that nonselective stimulation of both receptors is likely to have the higher therapeutic efficacies on diabetic nephropathy, whereas other studies propose that the selective activation of the B2R and inhibition of B1R could be beneficial in cardiovascular diseases. Further experimental and clinical investigations are warranted to evaluate the longterm efficacy of the selective and nonselective KKS modulation.
